Pfizer Stops Global Smoking Cessation Pill Distribution After Flagging Impurities: Report

  • After finding unacceptable levels of potential carcinogens called nitrosamines in certain Chantix (varenicline) lots, Pfizer Inc PFE has halted the worldwide distribution of the popular smoking cessation medicine.
  • A spokesman said the company believes the drug's benefits "outweigh the very low potential risks, if any, posed by nitrosamine exposure from varenicline on top of other common sources over a lifetime." 
  • The company said the pause in distribution is out of an abundance of caution and pending further testing.
  • The FDA approved Chantix in May 2006 as a prescription medication that, along with support, helps adults aged 18 and over quit smoking and is used for 12 to 24 weeks.
  • Pfizer's Chantix generated $919 million last year, down 17% Y/Y as COVID-19 curbs hampered demand. The drug faced its first U.S. generics starting in November.
  • Price Action: PFE shares are up 0.15% at $39.25 during the premarket session on the last check Friday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!